A Study of Orally Administered JBI-802 Alone or in Combination With Pembrolizumab for Patients With Non-small Cell Lung Cancer With an STK11 Mutation.
PHASE2RecruitingINTERVENTIONAL
Enrollment
30
Participants
Timeline
Start Date
April 29, 2025
Primary Completion Date
October 31, 2027
Study Completion Date
October 31, 2028
Conditions
Lung Cancer (NSCLC)
Interventions
DRUG
JBI-802
LSD1/HDAC6 Inhibitor
DRUG
Pembrolizumab
PD-1
Trial Locations (1)
45219
RECRUITING
The Christ Hospital, Cincinnati
All Listed Sponsors
lead
The Christ Hospital
OTHER
NCT07207395 - A Study of Orally Administered JBI-802 Alone or in Combination With Pembrolizumab for Patients With Non-small Cell Lung Cancer With an STK11 Mutation. | Biotech Hunter | Biotech Hunter